PCRX— Pacira BioSciences, Inc.

MaterialsPharmaceuticals$959M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$726.41B+3.6%	$700.97B+3.9%	$674.98B+101123.0%	$666.8M
Cost of goods sold	$149.75B-12.1%	$170.43B-7.7%	$184.67B+92561.1%	$199.3M
Research and development	$117.31B+43.8%	$81.58B+7.0%	$76.26B+89828.9%	$84.8M
Selling, general and administrative	$368.76B+25.4%	$294.10B+9.2%	$269.44B+105764.1%	$254.5M
Amortization of acquired intangible assets	$57.29B+0.0%	$57.29B+0.0%	$57.29B+99900.0%	$57.3M
Goodwill impairment	$0-100.0%	$163.24B	$0	$0
Contingent consideration gains, acquisition-related expenses, restructuring and other	$14.11B+83.2%	$7.70B+2288.1%	-$352.0M-3328.5%	$10.9M
Total operating expenses	$707.22B-8.7%	$774.34B+31.8%	$587.30B+96687.1%	$606.8M
Income (loss) from operations	$19.19B+126.2%	-$73.37B-183.7%	$87.67B+145966.6%	$60.0M
Interest income	$22.73B+15.5%	$19.69B+72.0%	$11.44B+251859.5%	$4.5M
Interest expense	-$17.45B-5.3%	-$16.57B+18.4%	-$20.31B-50695.5%	-$40.0M
(Loss) gain on early extinguishment of debt	-$983.0M-113.1%	$7.52B+144.4%	-$16.93B	$0
Other, net	-$6.62B-1674.8%	-$373.0M-100.5%	-$186.0M-1547.8%	-$11.3M
Total other (expense) income, net	-$2.32B-122.6%	$10.27B+139.5%	-$25.97B-55492.7%	-$46.7M
Income (loss) before income taxes	$16.87B+126.7%	-$63.11B-202.3%	$61.70B+463747.5%	$13.3M
Income tax expense	-$9.84B+73.0%	-$36.45B-84.6%	-$19.75B-757522.3%	$2.6M
Net income (loss)	$7.03B+107.1%	-$99.56B-337.3%	$41.95B+263618.6%	$15.9M
Basic net income (loss) per common share (in dollars per share)	$160.00+107.4%	-$2150.00-336.3%	$910.00+160.0%	$350.00
Diluted net income (loss) per common share (in dollars per share)	$160.00+107.4%	-$2150.00-341.6%	$890.00+161.8%	$340.00
Basic (in shares)	44.6M-3.6%	46.2M+0.0%	46.2M+1.5%	45.5M
Diluted (in shares)	45.0M-2.6%	46.2M-11.0%	52.0M+11.7%	46.5M
Net product sales
Royalty revenue

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.